Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences and Assembly Biosciences have announced a 12-year partnership to develop antiviral therapies, initially focusing on herpesviruses, Hepatitis B and D. Assembly Bio will receive a $100M upfront payment.
October 17, 2023 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Assembly Biosciences will receive a $100M upfront payment from Gilead Sciences as part of their 12-year partnership agreement.
The $100M upfront payment from Gilead Sciences will provide Assembly Biosciences with immediate capital, which could be used to fund its operations and research activities. This could potentially lead to a positive impact on its financial performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Gilead Sciences has entered into a long-term partnership with Assembly Biosciences, which could potentially lead to the development of new antiviral therapies.
The partnership with Assembly Biosciences could potentially lead to the development of new antiviral therapies, which would strengthen Gilead's product portfolio and potentially increase its revenues in the long term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100